ADD3: A Drug Target / Disease Biomarker (G120)

Target Name: ADD3

NCBI ID: G120

ADD3

ADD3: A Drug Target / Disease Biomarker

Attention Deficit Hyperactivity Disorder (ADHD) is a neurodevelopmental disorder that affects millions of people worldwide. It is characterized by symptoms such as difficulty paying attention, impulsivity, and hyperactivity. Despite the availability of several medications that can treat ADHD, the condition remains a significant public health issue.

One potential drug target for ADHD is the neurotransmitter dopamine. Dopamine is a chemical that plays a crucial role in the functioning of the brain, particularly in terms of attention and motor control. Imbalances in dopamine levels have been implicated in the development of ADHD.

One of the primary neurotransmitters involved in ADHD is norepinephrine. Norepinephrine is a hormone that is produced by the brain and helps to regulate the body's responses to various stimuli. In people with ADHD, there is a deficiency in the production of norepinephrine.

Research has suggested that individuals with ADHD may have lower levels of norepinephrine in their brains than those without the condition. This deficiency in norepinephrine may contribute to the symptoms of ADHD, such as difficulty with attention and hyperactivity.

Another neurotransmitter that has been implicated in ADHD is dopamine itself. Dopamine is involved in the formation of new connections in the brain, which is important for the development and maintenance of neural circuits. Research has suggested that individuals with ADHD may have lower levels of dopamine in their brains than those without the condition.

In addition to dopamine and norepinephrine, other neurotransmitters have also been implicated in ADHD. One such neurotransmitter is GABA, which is a chemical that helps to regulate the activity of other neurotransmitters, including dopamine. Individuals with ADHD may have lower levels of GABA in their brains than those without the condition.

Another potential drug target for ADHD is the neurotransmitter serotonin. Serotonin is involved in the regulation of mood, appetite, and sleep, and has been implicated in ADHD. Research has suggested that individuals with ADHD may have lower levels of serotonin in their brains than those without the condition.

In conclusion, the neurotransmitters dopamine, norepinephrine, and GABA have been implicated in the development and maintenance of ADHD. Imbalances in these neurotransmitter levels may contribute to the symptoms of ADHD, such as difficulty with attention and hyperactivity. Targeting these neurotransmitters using drugs may be a promising new approach to the treatment of ADHD.

Protein Name: Adducin 3

Functions: Membrane-cytoskeleton-associated protein that promotes the assembly of the spectrin-actin network. Plays a role in actin filament capping (PubMed:23836506). Binds to calmodulin (Probable). Involved in myogenic reactivity of the renal afferent arteriole (Af-art), renal interlobular arteries and middle cerebral artery (MCA) to increased perfusion pressure. Involved in regulation of potassium channels in the vascular smooth muscle cells (VSMCs) of the Af-art and MCA ex vivo. Involved in regulation of glomerular capillary pressure, glomerular filtration rate (GFR) and glomerular nephrin expression in response to hypertension. Involved in renal blood flow (RBF) autoregulation. Plays a role in podocyte structure and function. Regulates globular monomer actin (G-actin) and filamentous polymer actin (F-actin) ratios in the primary podocytes affecting actin cytoskeleton organization. Regulates expression of synaptopodin, RhoA, Rac1 and CDC42 in the renal cortex and the primary podocytes. Regulates expression of nephrin in the glomeruli and in the primary podocytes, expression of nephrin and podocinin in the renal cortex, and expression of focal adhesion proteins integrin alpha-3 and integrin beta-1 in the glomeruli. Involved in cell migration and cell adhesion of podocytes, and in podocyte foot process effacement. Regulates expression of profibrotics markers MMP2, MMP9, TGF beta-1, tubular tight junction protein E-cadherin, and mesenchymal markers vimentin and alpha-SMA (By similarity). Promotes the growth of neurites (By similarity)

The "ADD3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ADD3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets